**Specifications Table**TableSubject areaMedicineMore specific subject areaCardiovascular diseasesType of dataTable, graph, figuresHow data was acquiredErythrocyte omega-3 fatty acid proportions were measured at baseline in 3259 participants of the Ludwigshafen Risk and Cardiovascular Health Study (LURIC) using the HS-Omega-3 Index method. Associations of omega-3 fatty acid proportions with mortality were investigated using Cox proportional hazards regression.Data formatAnalyzedExperimental factorsFasting blood samples were obtained by venipuncture at study entry. Fatty acid methyl esters were generated from erythrocytes that had been stored at −80 °C by acid transesterification.Experimental featuresErythrocyte fatty acid composition was analyzed according to the HS-Omega-3 Index technology [@bib2]. Fatty acid methyl esters were analyzed by gas chromatography using a GC2010 gas chromatograph (Shimadzu, Duisburg, Germany) equipped with a 100-m SP2560 column (Supelco, Bellefonte, PA) and using hydrogen as carrier gas. Fatty acids were identified by comparison with a standard mixture of fatty acids characteristic of erythrocytes. Results are presented as a percentage of total identified fatty acids after response factor correction.Data source locationLudwigshafen Heart Center in South-West GermanyData accessibilityData is within this article.

**Value of the data**•Gender-stratified analysis allows the identification of gender-specific effects of omega-3 fatty acids.•Examination of nonlinear effects on mortality risk is important to define safe reference values.•Investigation of cause-specific mortality might provide hints to possible pathways affected by omega-3 fatty acids.

1. Data {#s0005}
=======

The data presented in this paper includes Figures and Tables that show the results of gender and subgroup stratified distribution of omega-3 fatty acids proportions in the LURIC study as well as multivariate adjusted analyses of their association with all-cause and cause-specific mortality that extend the results reported in [@bib1] ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"} and [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}).

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Subjects {#s0015}
-------------

The LURIC study consists of 3316 Caucasians with an indication for coronary angiography that were between 1997 and 2000 at the Ludwigshafen Heart Center in South-West Germany. A detailed description of the study can be found in Winkelmann et al. [@bib3]. The study was approved by the ׳Landesärztekammer׳ Ethics Committee of the Rheinland-Pfalz state in Germany. Informed written consent was obtained from all participants.

2.2. Laboratory procedures {#s0020}
--------------------------

The fatty acid composition of erythrocyte membranes was analyzed using the HS-Omega-3 Index® methodology as described in [@bib1], [@bib2]. Results are given as a percentage of total identified fatty acids after response factor correction.

2.3. Definition of clinical variables and endpoints {#s0025}
---------------------------------------------------

The definition of clinical endpoints is detailed in [@bib1], [@bib3]. The 2012 CKD-EPI eGFRcreat-cys equation was used to estimate the glomerular filtration rate [@bib4]. Information on vital status of study participants was requested from local registries. Cardiovascular mortality included sudden cardiac death (*n*=254, 7.8%), fatal myocardial infarction (*n*=104, 3.2%), death due to congestive heart failure (*n*=148, 4.5%), death after intervention to treat CAD (*n*=26, 0.8%), fatal stroke (*n*=60, 1.8%), and other causes of death due to CAD (*n*=19, 0.6%).

2.4. Statistical analyses {#s0030}
-------------------------

We present the mean and the standard deviation of continuous data when normally distributed and the median and 25th and 75th percentile for variables with a skewed distribution. Categorical data are presented as percentages. ANOVA was used to compare continuous variables between groups (variables with a skewed distribution were log-transformed before entering analysis) and the chi-square test was used for categorical variables. The association of omega-3 fatty acid levels in tertiles or as *Z*-transformed values with mortality was assessed by Cox proportional hazard regression with the same adjustments as in [@bib1]. Examination of scaled Schoenfeld residuals provided no evidence for a violation of the proportional hazard assumption. All tests were two-sided and a *p* value \<0.05 was considered statistically significant. SPSS v22.0 (IBM, Ehningen, Germany) and R v3.2.3 (<http://www.r-project.org>) were used for all analyses. The R-package ׳rms׳ was used for the generation of hazard ratio plots.
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![Proportions of omega-3 fatty acids in men and women. Box plots showing the distribution of ALA (A), EPA (B), DHA (C) and DPA (D) in LURIC stratified by gender. Boxes represent the interquartile ranges (IQR), median values are shown as black lines. Whiskers extend to the data point closest to a distance 1.5 times the IQR away from the median. ALA: α-linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; DPA: docosapentaenoic acid.](gr1){#f0005}

![Density distribution of omega-3 fatty acid levels in men and women. Density plots showing the density distributions of ALA (A), EPA (B), DHA (C) and DPA (D) stratified by gender. ALA: α-linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; DPA: docosapentaenoic acid.](gr2){#f0010}

![Association of omega-3 fatty acids with cardiovascular mortality. Forest plot showing the risk of CVM per 1-SD increase in omega-3 fatty acids. Hazard ratios and 95% CI were calculated for ALA, EPA, DHA and the HS-Omega-3 Index by Cox regression. Model 1: adjusted for age and gender; model 2: additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension, diabetes, smoking, alcohol consumption, physical exercise and lipid lowering therapy. ALA: α-linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; DPA: docosapentaenoic acid; TG: triglycerides.](gr3){#f0015}

![Association of omega-3 fatty acids with mortality additionally adjusted for hsCRP. Forest plot showing the risk of mortality per 1-SD increase in omega-3 fatty acids. Hazard ratios with 95% confidence intervals were calculated by Cox regression adjusted for age and gender, BMI, LDL-C, HDL-C, logTG, hypertension, diabetes, smoking, alcohol consumption, physical exercise, lipid lowering therapy and log hsCRP.](gr4){#f0020}

![Association of DPA with mortality. Forest plot showing the risk of all-cause mortality and CVM per 1-SD increase in DPA. Model 1: adjusted for age and gender; model 2: additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension, diabetes, smoking, alcohol consumption, physical exercise and lipid lowering therapy. DPA: docosapentaenoic acid.](gr5){#f0025}

![Association of omega-3 fatty acids with all-cause mortality stratified by CAD status. Hazard ratios and 95% CI were calculated for ALA, EPA, DHA and the HS-Omega-3 Index using Cox regression in patients with (A) and without (B) CAD at baseline. Model 1: adjusted for age and gender; model 2: additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension, diabetes, smoking, alcohol intake, physical exercise and lipid lowering therapy. ALA: α-linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; TG: triglycerides.](gr6){#f0030}

![Hazard ratio plots showing the relationship between EPA proportion and all-cause mortality. Results are shown for men (A) and women (B). In a Cox regression model including age, sex, BMI, LDL-C, HDL-C, TG, smoking, alcohol intake, diabetes mellitus, hypertension, physical exercise, lipid lowering therapy and EPA, the EPA proportion was modeled as restricted cubic spline with three knots and plotted against the log hazard. EPA: eicosapentaenoic acid.](gr7){#f0035}

###### 

Study characteristics stratified by gender (mean±SD or median and 25th--75th percentile).

Table 1

                                    **Male**            **Female**          *p*[a](#tbl1fna){ref-type="table-fn"}
  --------------------------------- ------------------- ------------------- ---------------------------------------
  Age (years)                       61.8 (64.7)         64.7 (10.2)         \<0.001
  BMI (kg/m^2^)                     27.6 (3.78)         27.3 (4.66)         0.103
  LDL-C (mmol/L)                    2.95 (0.84)         3.16 (0.98)         \<0.001
  HDL-C (mmol/L)                    0.97 (0.26)         1.08 (0.31)         \<0.001
  TG (mmol/L)                       1.67 (1.24--2.28)   1.63 (1.20--2.26)   0.016
  Systolic blood pressure (mmHg)    141 (23.2)          141 (24.6)          0.870
  Diastolic blood pressure (mmHg)   81.7 (11.5)         79.5 (11.4)         \<0.001
  Fasting glucose (mmol/L)          5.70 (5.23--6.59)   5.64 (5.14--6.56)   0.004
  hsCRP (mg/L)                      3.28 (1.24--8.63)   3.58 (1.45--8.63)   0.107
  NT-proBNP (ng/ml)                 286 (98.0--858)     313 (132--878)      0.002
  RBC ALA (%)                       0.118 (0.046)       0.123 (0.045)       0.001
  RBC EPA (%)                       0.77 (0.32)         0.75 (0.28)         0.053
  RBC DPA (%)                       2.47 (0.36)         2.36 (0.336)        \<0.001
  RBC DHA (%)                       5.05 (1.12)         5.12 (1.02)         0.102
  RBC HS-Omega-3 Index (%)          5.82 (1.33)         5.86 (1.19)         0.365
  CAD (%)                           83.6                64.7                \<0.001
  Diabetes mellitus (%)             40.1                39.0                0.586
  Hypertension (%)                  71.4                76.2                0.005
  Arrhythmia (%)                    15.4                13.1                0.930
  Smoking (active/ex/never) (%)     26.2/50.7/23.0      17.2/19.0/63.8      \<0.001
  Lipid lowering therapy (%)        50.6                43.9                \<0.001

*t*-test for continuous variables (non-normally distributed variables were log transformed before entering analysis), *χ*^2^ test for categorical variables.

###### 

Study characteristics according to tertiles of α-linoleic acid (mean±SD or median and 25th--75th percentile).

Table 2

                                    **ALA (% of total fatty acids)**                                           
  --------------------------------- ---------------------------------- ------------------- ------------------- ---------
  Age (years)                       63.5±10.6                          62.8±10.8           61.5±10.4           \<0.001
  Sex (% male)                      72.7                               69.3                65.4                0.001
  BMI (kg/m^2^)                     27.6±3.99                          27.4±4.07           27.5±4.18           0.455
  LDL-C (mg/dl)                     114±32.1                           117±35.1            120±36.4            \<0.001
  HDL-C (mg/dl)                     37.4±10.1                          39.3±11.2           40.5±11.4           \<0.001
  TG (mg/dl)                        136 (103--185)                     144 (107--197)      166 (120--236)      \<0.001
  LDL radius (nm)                   8.28±0.20                          8.28±0.23           8.28±0.24           0.815
  Systolic blood pressure (mmHg)    141±23.8                           141±23.4            141±23.6            0.967
  Diastolic blood pressure (mmHg)   80.1±11.6                          81.2±11.6           82.1±11.1           \<0.001
  Fasting glucose (mg/dl)           102 (92.7--118)                    103 (94.0--118)     103 (95.0--119)     0.104
  hsCRP (mg/L)                      4.28 (1.50--10.1)                  3.28 (1.33--8.35)   2.60 (1.12--6.18)   \<0.001
  NT-proBNP (ng/ml)                 367 (139--1029)                    278 (100--848)      214 (86.0--604)     \<0.001
  CAD (%)                           82.5                               75.4                73.5                \<0.001
  Diabetes (%)                      40.9                               39.9                37.9                0.357
  Hypertension (%)                  73.3                               72.2                72.9                0.821
  Arrhythmia (%)                    15.0                               16.0                12.9                0.147
  Smoking (active/ex/never) (%)     22.9/44.6/32.5                     23.0/36.9/40.1      24.8/40.1/35.1      0.001
  Lipid lowering therapy (%)        53.8                               47.4                42.0                \<0.001

ANOVA for continuous variables (non-normally distributed variables were log transformed before entering analysis), *χ*^2^ test for categorical variables.

###### 

Study characteristics according to tertiles of eicosapentaenoic acid (mean±SD or median and 25th--75th percentile).

Table 3

                                    **EPA (% of total fatty acids)**                                         
  --------------------------------- ---------------------------------- ------------------ ------------------ ---------
  Age (years)                       63.0±10.9                          62.3±11.0          62.8±9.9           0.261
  Sex (% male)                      68.8                               69.6               70.6               0.658
  BMI (kg/m^2^)                     27.4±4.0                           27.5±4.2           27.5±4.0           0.830
  LDL-C (mg/dl)                     112.1±32.4                         116.8±35.1         120.8±34.8         \<0.001
  HDL-C (mg/dl)                     37.0±10.1                          38.4±10.2          41.1±11.8          \<0.001
  TG (mg/dl)                        153(113--210)                      150(112--206)      136(102--187)      \<0.001
  LDL radius (nm)                   8.27±0.21                          8.28±0.23          8.30±0.22          0.015
  Systolic blood pressure (mmHg)    141±23.6                           140±23.9           142±23.4           0.295
  Diastolic blood pressure (mmHg)   80.7±11.5                          80.7±11.6          81.7±11.3          0.076
  Fasting glucose (mg/dl)           102(93.7--120)                     102(93.6--119)     102(93.6--116)     0.279
  hsCRP (mg/L)                      3.74(1.38--9.30)                   3.35(1.35--8.56)   3.02(1.18--7.99)   0.005
  NT-proBNP (ng/ml)                 352(136--1118)                     274(97.0--773)     248(98.0--756)     \<0.001
  CAD (%)                           78.7                               78.5               76.3               0.341
  Diabetes (%)                      43.2                               39.1               36.8               0.009
  Hypertension (%)                  73.9                               72.4               72.3               0.642
  Arrhythmia (%)                    15.5                               15                 13.6               0.446
  Smoking (active/ex/never) (%)     24.4/41.8/33.9                     24.2/38.7/37.0     21.8/42.7/35.5     0.210
  Lipid lowering therapy (%)        49.5                               49.7               46.4               0.224

ANOVA for continuous variables (non-normally distributed variables were log transformed before entering analysis), *χ*^2^ test for categorical variables.

###### 

Study characteristics according to tertiles of docosahexaenoic acid (mean±SD or median and 25th--75th percentile).

Table 4

                                    **DHA(% of total fatty acids)**                                         
  --------------------------------- --------------------------------- ------------------ ------------------ ---------
  Age (years)                       60.1±11.2                         62.6±10.5          65.3±9.46          \<0.001
  Sex (% male)                      72.4                              69.3               67.3               0.033
  BMI (kg/m^2^)                     27.2±4.1                          27.7±4.0           27.4±4.1           0.017
  LDL-C (mg/dl)                     117.4±33.2                        117.2±34.6         114.8±35.0         0.145
  HDL-C (mg/dl)                     38.9±10.8                         38.4±10.4          39.1±11.4          0.318
  TG (mg/dl)                        156(112--216)                     149(113--203)      135(102--187)      \<0.001
  LDL radius (nm)                   8.27±0.21                         8.28±0.23          8.29±0.22          0.114
  Systolic blood pressure (mmHg)    140±23.6                          141±23.8           142±23.4           0.237
  Diastolic blood pressure (mmHg)   81.3±11.7                         81.0±11.5          80.7±11.2          0.391
  Fasting glucose (mg/dl)           101(93.2--115)                    104(94.4--120.9)   102(93.4--119)     0.122
  hsCRP (mg/L)                      3.32(1.24--7.91)                  3.57(1.38--9.24)   3.34(1.23--8.54)   0.107
  NT-proBNP (ng/ml)                 276(95.8--757)                    292(105--934)      311(116--921)      0.013
  CAD (%)                           75.2                              78.5               79.9               0.026
  Diabetes (%)                      35.2                              42.3               41.8               0.001
  Hypertension (%)                  70.9                              74.3               73.5               0.187
  Arrhythmia (%)                    13.5                              13.8               16.9               0.051
  Smoking (active/ex/never) (%)     33.0/36.2/30.7                    23.5/42.4/34.0     13.8/44.5/41.7     \<0.001
  Lipid lowering therapy (%)        47.0                              48.5               50.2               0.315

ANOVA for continuous variables (non-normally distributed variables were log transformed before entering analysis), *χ*^2^ test for categorical variables.

###### 

Comparison of Cox regression analyses modeling EPA proportion as linear term or as restricted cubic spline adjusted for risk factors (model 2).

Table 5

                 **loglik**   **Chisq**   **Df**   ***p***
  -------------- ------------ ----------- -------- ----------
  *Combined*                                       
  Spline model   −7151.0                           
  Linear model   −7153.5      4.9778      1        0.02567
                                                     
  *Men*                                            
  Spline model   −5072.7                           
  Linear model   −5076.3      7.1767      1        0.007386
                                                     
  *Women*                                          
  Spline model   −1519.7                           
  Linear model   −1519.9      0.3817      1        0.5367

###### 

Association between omega-3 fatty acids and cause-specific death.

Table 6

                                                    **Death due to heart failure**           **Sudden cardiac death**   
  ----------------------------- ------------------- -------------------------------- ------- -------------------------- -------
  ***a-Linolenic acid***                                                                                                
  Model 1                       1st (≤0.10%)        1^reference^                             1^reference^               
                                2nd (0.11--0.13%)   0.75 (0.50--1.12)                0.154   0.77 (0.57--1.04)          0.088
                                3rd (≥0.14%)        0.96 (0.65--1.42)                0.838   0.96 (0.71--1.29)          0.761
  *p*~Trend~                                                                         0.346                              0.222
  Model 2                       1st (≤0.10%)        1^reference^                             1^reference^               
                                2nd (0.11--0.13%)   0.79 (0.53--1.19)                0.258   0.80 (0.59--1.09)          0.159
                                3rd (≥0.14%)        1.05 (0.69--1.58)                0.831   1.05 (0.77--1.44)          0.764
  *p*~Trend~                                                                         0.422                              0.252
  ***Eicosapentaenoic acid***                                                                                           
  Model 1                       1st (≤0.60%)        1^reference^                             1^reference^               
                                2nd (0.61--0.82%)   0.71 (0.49--1.04)                0.077   0.93 (0.69--1.24)          0.600
                                3rd (≥0.83%)        0.62 (0.42--0.93)                0.020   0.71 (0.52--0.98)          0.034
  *p*~Trend~                                                                         0.044                              0.094
  Model 2                       1st (≤0.60%)        1^reference^                             1^reference^               
                                2nd (0.61--0.82%)   0.77 (0.52--1.13)                0.184   0.98 (0.73--1.31)          0.886
                                3rd (≥0.83%)        0.69 (0.46--1.04)                0.076   0.75 (0.54--1.04)          0.081
  *p*~Trend~                                                                         0.167                              0.165
  ***Docosahexaenoic acid***                                                                                            
  Model 1                       1st (≤4.53%)        1^reference^                             1^reference^               
                                2nd (4.54--5.47%)   0.80 (0.53--1.20)                0.273   1.03 (0.76--1.41)          0.833
                                3rd (≥5.48%)        0.85 (0.57--1.26)                0.411   0.94 (0.69--1.28)          0.700
  *p*~Trend~                                                                         0.525                              0.815
  Model 2                       1st (≤4.53%)        1^reference^                             1^reference^               
                                2nd (4.54--5.47%)   0.76 (0.50--1.15)                0.197   0.95 (0.69--1.30)          0.741
                                3rd (≥5.48%)        0.84 (0.56--1.26)                0.388   0.91 (0.66--1.26)          0.574
  *p*~Trend~                                                                         0.425                              0.853
  ***HS-Omega-3 Index***                                                                                                
  Model 1                       1st (≤5.19%)        1^reference^                             1^reference^               
                                2nd (5.20--6.24%)   0.74 (0.49--1.10)                0.137   1.11 (0.82--1.50)          0.517
                                3rd (≥6.25%)        0.77 (0.52--1.13)                0.182   0.85 (0.62--1.16)          0.305
  *p*~Trend~                                                                         0.260                              0.212
  Model 2                       1st (≤5.19%)        1^reference^                             1^reference^               
                                2nd (5.20--6.24%)   0.73 (0.49--1.10)                0.133   1.04 (0.76--1.41)          0.822
                                3rd (≥6.25%)        0.78 (0.52--1.16)                0.221   0.82 (0.60--1.14)          0.242
  *p*~Trend~                                                                         0.278                              0.303

Model 1: adjusted for age and gender.

Model 2: additionally adjusted for LDL-C, HDL-C, logTG, BMI, hypertension, diabetes mellitus, smoking, alcohol intake, physical exercise and lipid lowering therapy.

[^1]: Both authors contributed equally.
